With the ASX in a better mood, 4D Medical climbs 7% back to $4.30/sh

4D Medical (ASX:4DX) appears to be back on investors’ radars on Monday as the stock climbed nearly +7% back to $4.30/sh in mid-arvo trades.

The stock has remained popular with swing traders through the last few months of geopolitical trouble, ranging between around $4.30 and $3.30 depending, it seems, on the prevailing risk sentiment around the market broadly as opposed to company news or healthcare trends.

(To be fair, the Health Care sector was up +0.7% itself in mid-arvo trades on Monday.)

The company, which develops software for lung imaging purposes and licences that tech, has inked deals with Mayo Clinic – one of the world’s most respected cancer research entities – as well as Stanford University.

It was hotly popular in late 2025 and early 2026, hitting a record high of $6.80/sh in early-mid April before plummeting downwards as short selling increased.

In mid-July, short selling coverage of 4D Medical shares hit a peak of 13.4% of all shares on issue, and while positions have eased the stock still remains highly shorted at more than 11% of shares on issue.

No news came from the company on Monday and nor have there been any media reports about the company hitting popular publications; as at 2.15pm AEDT some $14.3M worth of shares had traded hands, more or less in line with 4wavg liquidity.

In late August the company reported it’d begun commercial deployment of its CT:VQ lung imaging tech after ending June with $278M in cash. That the company appears unlikely to spring surprise capital raises on investors is one element of its popularity, along with its overall value prop for the medical sector.

The company has also seen its tech published in the American Journal of Respiratory and Critical Care Medicine which underlined the benefits of CT:VQ, finding it was able to increase the proportion of patients responding to select surgeries by way of refining patient eligibility.

Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.